Latest News and Press Releases

FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and...

Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology...

Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the...

Completes Evaluation of Strategic Alternatives for Tissue Health Plus Segment  FORT WORTH, TX, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”)...

FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing...

EDEN PRAIRIE, Minn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...

Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the...

FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device...

Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation...